A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2019
At a glance
- Drugs Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 12 Oct 2018 Planned primary completion date changed from 5 Apr 2020 to 27 May 2019.
- 31 Aug 2018 Biomarkers information updated
- 11 May 2018 Status changed from not yet recruiting to recruiting.